Flupirtin as Oral Treatment in MS

Flupirtin as Oral Treatment in MS

CompletedPhase 2Relapsing MS2006-005262-39

What was tested

Treatment tested

  • Flupirtin

What it measured

Main measures

  • Primary objectives are the incidence of new T2-lesions, the number of patients without newly occurring T2 lesions over the treatmant period, "lesion load", number and volume of "black holes", "brain parenchymal fraction" measured by cerebral MRI and changes in the relation of NAA and choline measured by MRS.

    MRI lesionsBrain volume loss

Papers

    Loading reviews and guidelines…

    History

    1. In scope changed from true to false

    1. Started

      Mar 2007

    Assembled by software from public sources.